Profile data is unavailable for this security.
About the company
Jiangsu Aidea Pharmaceutical Group Co Ltd, formerly Jiangsu Aidea Pharmaceutical Co Ltd, is a China-based company mainly engaged in the research and development, production and sales of anti-human immunodeficiency virus (HIV) drugs and human protein products. The Company is also engaged in the business of HIV diagnostic equipment and reagents. The Company's human protein products mainly include crude ulinastatin, crude urokinase and crude urokinase. The Company’s drugs include products Ainuovirine, Lamivudine and Tenofovir Disoproxil Fumarate Tablets, Ainuovirine Tablets, Sennae Folium Granules and Live Bacillus Cereus Tablets. The Company mainly distributes its products within the domestic market.
- Revenue in CNY (TTM)671.33m
- Net income in CNY-87.10m
- Incorporated2009
- Employees704.00
- LocationJiangsu Aidea Pharmaceutical Group Co LtdNo. 69Xinganquan West Road, Hanjiang DistrictYANGZHOU 225008ChinaCHN
- Phone+86 51 482090238
- Fax+86 51 487736366
- Websitehttp://www.aidea.com.cn/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shanghai OPM Biosciences Co Ltd | 352.91m | 43.24m | 6.85bn | 328.00 | 140.33 | 2.84 | -- | 19.40 | 0.3751 | 0.3751 | 3.18 | 18.51 | 0.1558 | 2.50 | 4.05 | 1,075,953.00 | 1.88 | 3.50 | 1.96 | 3.69 | 50.40 | 57.44 | 12.09 | 21.40 | 15.47 | -- | 0.0272 | 58.30 | 22.26 | 38.41 | -61.04 | -- | 43.46 | -- |
| Shanghai Fudan-Zhangjiang Bio-Pharm. Co | 711.63m | -62.67m | 7.07bn | 925.00 | -- | 3.96 | -- | 9.94 | -0.0605 | -0.0605 | 0.6865 | 2.18 | 0.2795 | 2.02 | 2.18 | 769,331.60 | -2.47 | 5.01 | -2.70 | 6.20 | 88.90 | 91.92 | -8.83 | 14.50 | 8.51 | -11.45 | 0.007 | 48.29 | -16.61 | -7.17 | -63.42 | -29.45 | 1.11 | -- |
| Shanghai Haixin Group Co Ltd | 788.05m | 156.25m | 7.08bn | 715.00 | 64.45 | 2.16 | -- | 8.98 | 0.1294 | 0.1294 | 0.6529 | 3.87 | 0.1404 | 5.99 | 8.40 | 1,102,168.00 | 3.13 | 2.89 | 3.42 | 3.27 | 51.52 | 46.43 | 22.33 | 12.82 | 4.42 | -- | 0.0209 | 35.43 | -32.70 | -6.47 | -9.09 | 7.75 | -34.08 | 5.92 |
| Jiangsu Aidea Pharmaceutical Group Co Ld | 671.33m | -87.10m | 7.36bn | 704.00 | -- | 7.53 | -- | 10.97 | -0.207 | -0.207 | 1.60 | 2.32 | 0.3558 | 1.01 | 4.33 | 953,592.70 | -3.23 | -4.33 | -5.23 | -5.36 | 63.08 | 40.16 | -9.09 | -20.35 | 1.03 | -2.12 | 0.3093 | -- | 1.57 | 3.89 | -85.63 | -- | 5.88 | -- |
| Lushang Freda Pharmaceutical Co Ltd | 3.78bn | 214.11m | 7.39bn | 3.63k | 34.43 | 1.77 | -- | 1.96 | 0.2112 | 0.2112 | 3.72 | 4.12 | 0.633 | 3.37 | 7.63 | 1,040,448.00 | 4.45 | 0.7994 | 6.29 | 5.29 | 51.41 | 23.96 | 7.02 | 3.71 | 3.96 | -- | 0.0393 | 43.21 | -13.02 | -17.29 | -19.73 | -6.70 | 21.16 | 0.00 |
| Wuhan Keqian Biology Co Ltd | 1.01bn | 459.54m | 7.57bn | 924.00 | 16.57 | 1.81 | -- | 7.46 | 0.9796 | 0.9796 | 2.16 | 8.95 | 0.2209 | 2.86 | 3.23 | 1,097,706.00 | 9.97 | 11.71 | 11.17 | 13.56 | 65.26 | 73.57 | 45.16 | 44.51 | 5.02 | -- | 0.0017 | 32.23 | -11.48 | 13.17 | -3.43 | 9.52 | -4.93 | -- |
| Heilongjiang ZBD Pharmaceutical Co Ltd | 1.60bn | -332.62m | 7.65bn | 2.35k | -- | 1.05 | -- | 4.79 | -0.3545 | -0.3545 | 1.70 | 7.75 | 0.1303 | 0.6358 | 0.4977 | 679,399.90 | -2.74 | 3.29 | -3.80 | 4.46 | 44.16 | 37.24 | -21.03 | 10.59 | 1.33 | -1.45 | 0.3114 | 24.43 | -13.90 | -3.87 | -7.30 | 1.41 | 1.13 | -7.12 |
| Cisen Pharmaceutical Co Ltd | 3.56bn | 492.80m | 7.76bn | 3.30k | 15.81 | 1.26 | -- | 2.18 | 1.08 | 1.08 | 7.84 | 13.59 | 0.472 | 2.10 | 5.34 | 1,079,074.00 | 6.58 | 6.51 | 8.12 | 8.07 | 53.70 | 55.92 | 13.94 | 10.84 | 3.48 | -- | 0.0069 | 37.16 | -10.77 | -0.6464 | -2.38 | -0.2215 | -0.3051 | 10.42 |
| China Animal Husbandry Industry Co., Ltd | 6.28bn | 214.44m | 7.83bn | 4.30k | 36.52 | 1.37 | -- | 1.25 | 0.21 | 0.21 | 6.15 | 5.60 | 0.6863 | 5.30 | 4.19 | 1,461,064.00 | 2.32 | 5.25 | 3.37 | 7.48 | 15.59 | 22.15 | 3.38 | 7.31 | 1.62 | -- | 0.1625 | 31.16 | 11.30 | 7.79 | -82.41 | -22.24 | -0.0699 | -21.83 |
Data as of Feb 13 2026. Currency figures normalised to Jiangsu Aidea Pharmaceutical Group Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
21.64%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Aegon-Industrial Fund Management Co., Ltd.as of 30 Jun 2025 | 10.23m | 4.74% |
| Penghua Fund Management Co., Ltd.as of 30 Jun 2025 | 10.09m | 4.68% |
| China Merchants Fund Management Co., Ltd.as of 30 Jun 2025 | 6.85m | 3.18% |
| China Fund Management Co., Ltd.as of 30 Jun 2025 | 4.10m | 1.90% |
| GF Fund Management Co., Ltd.as of 30 Jun 2025 | 4.02m | 1.86% |
| ABC-CA Fund Management Co., Ltd.as of 30 Jun 2025 | 3.91m | 1.81% |
| Bank of China Investment Management Co., Ltd.as of 30 Jun 2025 | 2.31m | 1.07% |
| Huashang Fund Management Co., Ltd.as of 30 Jun 2025 | 1.82m | 0.84% |
| Orient Securities Asset Management Co. Ltd.as of 30 Jun 2025 | 1.71m | 0.79% |
| ICBC UBS Asset Management Co. Ltd.as of 30 Jun 2025 | 1.63m | 0.76% |
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
